The arrival of Wegovy 7.2mg is one of the biggest developments we have seen in medical weight management in the UK in years. For patients who have already had success with semaglutide but want stronger support to continue progressing, higher strength Wegovy could be a genuine step forward.
At The Care Pharmacy, we’re ready. We’ve been watching the rollout closely, preparing our clinical processes, and ensuring we are positioned to stock and supply Wegovy 7.2mg responsibly as part of a structured and supported weight loss journey.
If you’re ready to explore your options now, reach out to us or start an online consultation with our clinical team today.
Wegovy 7.2mg is a higher dose of semaglutide taken once per week, designed to offer greater appetite regulation and improved weight loss outcomes in eligible adults living with obesity.
Until now, the highest standard maintenance dose of Wegovy in the UK has been 2.4mg once weekly. The move to a 7.2mg dose is significant because it gives the medication more scope to work for patients who need stronger appetite suppression or have plateaued at lower doses.
It is important to understand that Wegovy 7.2mg is not a “starter dose”. It is a higher maintenance option, and patients will still need to follow the recommended titration schedule under clinical supervision.
Wegovy injections have already helped thousands of people lose weight by reducing hunger, increasing feelings of fullness, and making it easier to stick to healthier portion sizes.
What makes higher strength Wegovy exciting is that it may offer:
As an online provider, we also see another benefit. When dosing options expand, it gives clinicians more flexibility to tailor treatment properly to each person, rather than forcing a one-size-fits-all all approach.
According to the MHRA, trials showed that a third of adult participants living with obesity who took the higher dose once a week achieved weight loss of more than 25 per cent or more after 72 weeks.
That is an impressive figure, and it reinforces why this new option is being discussed as a major shift in how weight loss medication may be prescribed and supported going forward.
Both doses contain the same active ingredient (semaglutide), meaning they work in the same general way. The difference is strength, which can influence results, appetite reduction, and tolerability.
Here is a simple comparison table to show how Wegovy 7.2mg differs from the previous highest dose.
| Feature | Wegovy 2.4mg (Previous Highest Dose) | Wegovy 7.2mg (Higher Strength Wegovy) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Dose strength | 2.4mg once weekly | 7.2mg once weekly |
| How it is taken | Injection | Injection |
| Main purpose | Standard maintenance dose | Enhanced maintenance support for eligible patients |
| Expected effect on appetite | Strong appetite regulation | Potentially stronger appetite suppression |
| Who it may suit | Patients progressing through standard Wegovy schedule | Patients who need more support after reaching 2.4mg |
Recent UK reporting has confirmed that the MHRA has approved a stronger 7.2mg dose of Wegovy.
At The Care Pharmacy, we have been planning for this shift to ensure you get the best support available. Our goal is always to provide trusted access to medication with clinical oversight, not rushed supply or unsafe shortcuts.
This is exactly why our team is already locked and loaded, with systems ready to help eligible patients access Wegovy 7.2mg safely, once supply and prescribing pathways allow.
If you are currently using weight loss injections or thinking about starting, you can start an online consultation with us to explore Wegovy and other suitable options.
Not necessarily. Higher doses do not automatically mean better for every patient.
Some people achieve excellent results on the standard 2.4mg dose, especially when lifestyle changes are consistent. Others may need a stronger dose due to weight loss slowing down over time, or appetite returning.
A careful clinical review matters because factors like side effects, medical history, and progress all need to be considered.
At The Care Pharmacy, we support patients with a full range of trusted weight loss treatments, including:
We are also excited to anticipate the introduction of the first Wegovy pill in the UK later this year, and are geared up to begin providing this as soon as it hits the UK market.
We take pride in staying ahead of the trend, investing in clinical pathways and patient education so that when new medication developments reach the UK, we are best placed to help patients benefit from them properly.
Wegovy is a tool, not a replacement for healthy habits. Even with Wegovy 7.2mg, your long-term results will still depend on the foundations:
The real advantage of weight loss medication is that it makes lifestyle changes easier to stick to. The appetite reduction helps you follow through, and clinical support keeps you on track.
No. Wegovy is typically introduced through gradual dose increases to reduce side effects. Wegovy 7.2mg is a higher maintenance dose for eligible patients.
Early results suggest it may help some patients achieve greater overall weight loss. The MHRA has highlighted strong trial outcomes at the higher dose.
Side effects can be more noticeable at higher doses for some people, particularly nausea or digestive upset. This is why medical supervision and dose progression matter.
This depends on your clinical history and response. Switching medications should always be done with professional oversight to ensure safety and suitability.
The introduction of Wegovy 7.2mg marks a new chapter in UK medical weight loss. For eligible patients, higher strength Wegovy could offer stronger appetite control and improved long-term results, with the right plan in place.
At The Care Pharmacy, we’re ready to support you with safe access, trusted clinical guidance, and the latest weight loss treatments as they become available.
Contact us today or start an online consultation to take the next step.
This blog was written in collaboration with Pharmacy Mentor.
Medically reviewed by
Superintendent Pharmacist
Weight Loss · Emerging Treatments Cagrilintide: What It Is, How It Works, and Why It Could Change Weight Loss Medicine Everything you need to know about the next generation of obesity treatment — and what happens when it’s combined with a GLP-1. Updated June 2026 · Medically reviewed · 12 min read Important: This guide […]
Wegovy Pill MHRA-Approved UK: Let’s dig into a bit more… Medically reviewed by Mohammed Ismail Lakhi, MPharm, MRPharmS — Superintendent Pharmacist, GPhC Reg. 2072815 | Last updated: 12 June 2026 The Wegovy Pill has been approved in the UK. On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy tablets (oral […]
Starting a new prescription medication always comes with questions. When that medication is as clinically potent as Mounjaro (tirzepatide), those questions tend to centre on one thing above all else: the side effects. What will they feel like? When will they start? And, perhaps most importantly, how long do Mounjaro side effects last? This guide […]
Starting Mounjaro is one thing. Getting the most from it is another. The clinical evidence for tirzepatide is compelling, but the patients who achieve the best outcomes are not simply those who inject once a week and hope for the best. They are the patients who understand how the medication works, adapt their habits to […]
Weight management on the NHS is available, and for many patients it remains an excellent option. But it is not accessible to everyone, and for those who do qualify, waiting times have become a significant barrier. As NHS weight management lists grow longer and the demand for prescription weight loss treatment continues to rise, a […]
Search for Wegovy before and after online and you will find an overwhelming volume of content: dramatic transformation photographs, monthly progress videos, and side-by-side comparisons shared across Instagram, TikTok, and Facebook. Some of this content is genuine. Much of it is misleading. And some of it is actively dangerous, not because of what it shows, […]
